D Vázquez-Abad1, N F Rothfield. 1. Division of Rheumatic Diseases, University of Connecticut School of Medicine, Farmington 06030-1310, USA.
Abstract
OBJECTIVE: To determine the sensitivity and specificity of anti-Jo-1 in systemic sclerosis (SSc) patients with and without myositis. METHODS: Immunoblots on HeLa nuclei were used to screen sera from 554 consecutive connective tissue disease patients. Those who had 45-55-kd bands, all patients with polymyositis/dermatomyositis (PM/DM), and a random selection of SSc, Raynaud's disease, systemic lupus erythematosus, and rheumatoid arthritis patients were also studied by anti-Jo-1 enzyme-linked immunosorbent assay and by immunoblots on rabbit pooled aminoacyl-transfer RNA synthetase. RESULTS: Anti-Jo-1 was present only in 8 of the 40 PM/DM patients. CONCLUSION: Anti-Jo-1 is specific for PM/DM.
OBJECTIVE: To determine the sensitivity and specificity of anti-Jo-1 in systemic sclerosis (SSc) patients with and without myositis. METHODS: Immunoblots on HeLa nuclei were used to screen sera from 554 consecutive connective tissue disease patients. Those who had 45-55-kd bands, all patients with polymyositis/dermatomyositis (PM/DM), and a random selection of SSc, Raynaud's disease, systemic lupus erythematosus, and rheumatoid arthritispatients were also studied by anti-Jo-1 enzyme-linked immunosorbent assay and by immunoblots on rabbit pooled aminoacyl-transfer RNA synthetase. RESULTS: Anti-Jo-1 was present only in 8 of the 40 PM/DMpatients. CONCLUSION: Anti-Jo-1 is specific for PM/DM.
Authors: G J D Hengstman; L van Brenk; W T M Vree Egberts; E L van der Kooi; G F Borm; G W A M Padberg; W J van Venrooij; B G M van Engelen Journal: J Neurol Date: 2005-02-23 Impact factor: 4.849